181 related articles for article (PubMed ID: 1300216)
1. On assessment of bioequivalence under a higher-order crossover design.
Chow SC; Liu JP
J Biopharm Stat; 1992; 2(2):239-56. PubMed ID: 1300216
[TBL] [Abstract][Full Text] [Related]
2. A note on sample size determination for bioequivalence studies with high-order crossover designs.
Chen KW; Chow SC; Li G
J Pharmacokinet Biopharm; 1997 Dec; 25(6):753-65. PubMed ID: 9697082
[TBL] [Abstract][Full Text] [Related]
3. Bioequivalence and intrasubject variability.
Liu JP
J Biopharm Stat; 1991; 1(2):205-19. PubMed ID: 1844697
[TBL] [Abstract][Full Text] [Related]
4. Assessment of bioequivalence using a multiplicative model.
Chow SC; Peace KE; Shao J
J Biopharm Stat; 1991; 1(2):193-203. PubMed ID: 1844696
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of parametric and nonparametric two one-sided tests procedures for assessing bioequivalence of average bioavailability.
Liu JP; Weng CS
J Biopharm Stat; 1993 Mar; 3(1):85-102. PubMed ID: 8485538
[TBL] [Abstract][Full Text] [Related]
6. Extension to the use of tolerance intervals for the assessment of individual bioequivalence.
Esinhart JD; Chinchilli VM
J Biopharm Stat; 1994 Mar; 4(1):39-52. PubMed ID: 8019583
[TBL] [Abstract][Full Text] [Related]
7. A two one-sided tests procedure for assessment of individual bioequivalence.
Liu J; Chow SC
J Biopharm Stat; 1997 Mar; 7(1):49-61. PubMed ID: 9056588
[TBL] [Abstract][Full Text] [Related]
8. Effect of gastric emptying and entero-hepatic circulation on bioequivalence assessment of ranitidine.
Chrenova J; Durisova M; Mircioiu C; Dedik L
Methods Find Exp Clin Pharmacol; 2010; 32(6):413-9. PubMed ID: 20852750
[TBL] [Abstract][Full Text] [Related]
9. The assessment of individual and population bioequivalence.
Chinchilli VM
J Biopharm Stat; 1996 Mar; 6(1):1-14. PubMed ID: 8838775
[TBL] [Abstract][Full Text] [Related]
10. Bioequivalence of a single 10-mg dose of finasteride 5-mg oral disintegrating tablets and standard tablets in healthy adult male Han Chinese volunteers: a randomized sequence, open-label, two-way crossover study.
Chen L; Jiang X; Huang L; Lan K; Wang H; Hu L; Ren J; Li X; Zou Q
Clin Ther; 2009 Oct; 31(10):2242-8. PubMed ID: 19922895
[TBL] [Abstract][Full Text] [Related]
11. Average bioequivalence for two-sequence two-period crossover design with incomplete data.
Lee JY; Kim BC; Park SG
J Biopharm Stat; 2005; 15(5):857-67. PubMed ID: 16078389
[TBL] [Abstract][Full Text] [Related]
12. The analysis of bioequivalence with respect to TMAX under a 2 x 2 crossover design.
Have TR; Ten Chinchilli VM
J Biopharm Stat; 1995 Jul; 5(2):185-99. PubMed ID: 7581427
[TBL] [Abstract][Full Text] [Related]
13. Cost-efficient higher-order crossover designs in comparative bioavailability studies.
Zhou J; Yuan Y; Reynolds R; Raber S; Li Y
Clin Pharmacokinet; 2006; 45(6):623-32. PubMed ID: 16719543
[TBL] [Abstract][Full Text] [Related]
14. Use of the repeated cross-over designs in assessing bioequivalence.
Liu JP
Stat Med; 1995 May 15-30; 14(9-10):1067-78; discussion 1079-80. PubMed ID: 7569501
[TBL] [Abstract][Full Text] [Related]
15. Types of bioequivalence and related statistical considerations.
Hauck WW; Anderson S
Int J Clin Pharmacol Ther Toxicol; 1992 May; 30(5):181-7. PubMed ID: 1592546
[TBL] [Abstract][Full Text] [Related]
16. Analysis of multiple-dose bioequivalence studies.
Chinchilli VM; Esinhart JD; Barr WH
J Biopharm Stat; 1994 Nov; 4(3):423-35. PubMed ID: 7881454
[TBL] [Abstract][Full Text] [Related]
17. A three-step procedure for assessing bioequivalence in the general mixed model framework.
Vuorinen J; Turunen J
Stat Med; 1996 Dec; 15(24):2635-55. PubMed ID: 8981677
[TBL] [Abstract][Full Text] [Related]
18. Design and analysis issues for crossover designs in phase I clinical studies.
Boon PC; Roes KC
J Biopharm Stat; 1999 Mar; 9(1):109-28. PubMed ID: 10091913
[TBL] [Abstract][Full Text] [Related]
19. Robust and bootstrap testing procedures for bioequivalence.
Shen CF; Iglewicz B
J Biopharm Stat; 1994 Mar; 4(1):65-90. PubMed ID: 8019585
[TBL] [Abstract][Full Text] [Related]
20. Bioequivalence of two film-coated tablets of imatinib mesylate 400 mg: a randomized, open-label, single-dose, fasting, two-period, two-sequence crossover comparison in healthy male South American volunteers.
Parrillo-Campiglia S; Ercoli MC; Umpierrez O; RodrÃguez P; Márquez S; Guarneri C; Estevez-Parrillo FT; Laurenz M; Estevez-Carrizo FE
Clin Ther; 2009 Oct; 31(10):2224-32. PubMed ID: 19922893
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
